Overall Survival - HealthQuill

Merck & Co., Inc.’s drug Keytruda, along with Gilead Sciences Inc.'s antibody-drug conjugate, cut the risk of an aggressive breast cancer advancement and death by 35% during an end-stage trial.

Merck, Gilead’s drug for breast cancer cuts progression risk by 35 per cent

HQ Team June 1, 2025: Merck & Co., Inc.’s drug Keytruda, along with Gilead Sciences Inc.’s antibody-drug conjugate, cut the risk of an.

by HealthQuill
June 1, 2025
0 Comments

Britain’s Medicines and Healthcare products Regulatory Agency has authorised GSK Plc’s combination drug to treat patients with multiple myeloma who have received at least one prior therapy.

Drugs Health Pharma

Britain gives green light for GSK Plc’s treatment of rare blood cancer

HQ Team April 18, 2025: Britain’s Medicines and Healthcare products Regulatory Agency has authorised GSK Plc’s combination drug to treat patients with multiple.

by HealthQuill
April 18, 2025
0 Comments

Johnson & Johnson’s combination therapy for treating a certain form of cancer without chemotherapy, has been shown to extend patients' lives by more than a year, according to a company statement.

Drugs Health Medical Pharma

J&J’s combination extends lives of cancer patients versus rival drug

Johnson & Johnson’s combination therapy for treating a certain form of cancer without chemotherapy, has been shown to extend patients' lives by more.

by HealthQuill
January 8, 2025
0 Comments

Merck & Co., Inc., announced it has met one of the primary goals during a late-stage trial of its breast cancer therapy, Keytruda.

Drugs Pharma

AstraZeneca, Merck announce promising results for breast cancer in trial 3

Bharti Jayshankar December 13, 2024: AstraZeneca and Merck have announced long-term results from the OlympiA Phase 3 trial, showing that Lynparza (olaparib) significantly.